Annals of Surgical Oncology Хирургия

Cryoablation: A Minimally Invasive Alternative for Early-Stage Breast Cancer: 6-Year Outcomes of the FROST Clinical Trial

D. R. Holmes, S. Manoian, R. Layeequr Rahman, R. C. Ward, N. Z. Carp, M. Plaza, K. Kozlowski, S. Abe, L. Bailey, L. Kruper, V. Jones, S. Patterson, J. Tamayo, P. Littrup
Springer Nature · 2026-01-15 · DOI 10.1245/s10434-025-18991-2

Аннотация

Abstract Background Cryoablation is emerging as a minimally invasive alternative to lumpectomy for select women with early-stage breast cancer. The FROST trial (NCT01992250) was a prospective, phase 2 multicenter study evaluating the outcome of cryoablation in the management of stage I, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative invasive ductal carcinoma. Methods Women 50 years old or older with unifocal, ultrasound-visible tumors were stratified by age: stratum 1 (age ≥70 years, endocrine therapy only) and stratum 2 (age 50–69 years, endocrine therapy + radiotherapy + optional sentinel node biopsy). Cryoablation was performed using a single cryoprobe under ultrasound guidance. Core biopsy 6 months after ablation was performed to confirm complete ablation. Patients were followed with clinical exams and imaging. Results The study included 83 completed cryoablations and follow-up evaluations. The median tumor size was 9 mm. More than 85% of the subjects in each group received endocrine therapy (stratum 1 [89%, 43/48], stratum 2 [85.7%, 30/35]) and 74.3% (26/35) of the subjects in stratum 2 received recommended whole-breast radiation. Of the 83 patients, 82 received a post-ablation core biopsy 6 months after cryoablation showing no residual cancer, and 1 patient declined a core biopsy. During a median follow-up period of 6.1 years, the 5-year ipsilateral breast tumor recurrence rate (IBTR) was 3.64% overall (stratum 1, 2.08%; stratum 2, 5.80%). The invasive IBTR-free survival rate was 97.59% overall (stratum 1, 97.92%; stratum 2, 97.14%). No serious adverse events occurred. Conclusions The FROST trial adds to the growing body of literature supporting the efficacy and safety of cryoablation and supports ongoing research on cryoablation as a strategy for de-escalating breast cancer therapy.

Читать у издателя →